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Abstract
Background: Hemoglobin A2’ (delta 16 Gly ® Arg) is globally the commonest delta chain variant of HbA2. It is
clinically and hematologically silent but its sole importance lies in the underestimation of HbA2 quantity during the
workup of b-thalassaemia trait. High performance liquid chromatography (HPLC) identifies it as a small S-window
peak with a mean retention time of 4.59 ± 0.03 minutes. This study aims at describing the frequency of detection
of HbA2’ by HPLC in Pakistan and its confirmation at a molecular level. Potential HbA2’ cases were identified by a
retrospective review of 10186 HPLC chromatograms in year 2006. Prospective samples were collected for
polymerase chain reaction (PCR) amplification, restriction digestion and nucleotide sequencing.
Findings: One hundred and ninety two potential cases (1.89%) of HbA2’ were detected on HPLC, having mean
retention time of 4.59 ± 0.05 minutes. Sixty four (0.6%) new cases were suspected of having co-existing b-
thalassaemia trait when the quantity of S-window peaks was taken into account. Thirteen samples with presumed
HbA2’ on HPLC were subjected to molecular analysis and the said mutation (δ 16 GGC ® CGC) was not detected
in any sample.
Conclusions: It is concluded that diagnosis of HbA2’ on HPLC alone is not justified, as evidence of the presence of
this delta chain variant in Pakistani population is yet to be proven. Such small S-window peaks should be either
disregarded or confirmed at molecular level, and only then should influence the diagnosis of b-thalassaemia trait.
Further studies are required to determine the true nature of these peaks.
Background
Hemoglobin (Hb) A2’, also called HbB2 or HbA2δ’,i s
globally the commonest δ chain variant of HbA2. It was
first discovered in 1958 in black community of Gulla
James Island [1]. Since then it has been reported with
increasing frequency among blacks with prevalence
being 2.16% in Mauritania (Northwestern Africa) [2],
2.7% in Dogon (Mali) [3] and 18% in Herero (South
Africa) [4]. Recently, this hemoglobinopathy has been
observed in two Brazilian Caucasian women [5], and in
white British [6].
HbA2’ is a clinically silent hemoglobinopathy that
results from modification of δ globin gene (GGC ®
CGC) substituting glycine for arginine at codon 16 [3].
This genetic disorder has been detected in
homozygous [7] and heterozygous states [8], and may
also be co-inherited with HbS [9], b-thalassaemia traits
[10] and other minor hemoglobinopathies. The clinical
significance of identification of HbA2’ is in the detection
of co-existing b-thalassaemia trait as, in the presence of
HbA2’, such individual might present with normal HbA2
levels resulting in under diagnosis of thalassaemia minor
[11]. Hence, it is important to screen patients for HbA2’.
Alkaline electrophoresis has limited resolution in this
regard [12] and though detection by iso-electric focusing
is easy, it lacks precise quantification [12]. On the other
hand, microcolumn chromatography can accurately mea-
sure total HbA2 level without identifying HbA2’[6]. In
contrast to these diagnostic tools, high performance
liquid chromatography (HPLC) not only senses HbA2’ as
it elutes in the ‘S’ window (retention time of 4.59 ± 0.03
minutes) but also quantifies it which is usually in propor-
tion of 1.2% of total hemoglobin [13].
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tion of hemoglobinopathies in year 2000 and though
minor peaks in S window were observed frequently,
they were largely ignored as unexplained peaks. Recent
literature review raised the possibility of them represent-
ing HbA2’ [6,14]. Although HbA2’ has never been
reported in Pakistan, the possibility of a rare silent
mutation existing in the country without being reported
was very likely owing to the fact that limited research
occurs here.
The objectives of the study were to evaluate the fre-
quency of detection of small S-window peaks represen-
tative of HbA2’ cases by HPLC and to confirm the
presence of HbA2’ mutation at a molecular level in
Pakistani population.
Hypothesis
Small S-window peaks on chromatography are second-
ary to the presence of HbA2’ in the blood samples.
Methods
Variant b-thalassaemia short program (Bio-Rad Labora-
tories, Hercules, CA, USA) utilizing the principle of
cation exchange high performance liquid chromatogra-
phy was used for detection of hemoglobin variants. We
retrospectively reviewed all HPLC chromatograms for
the year 2006. To define a diagnostic criteria for HbA2’,
we identified S-window peaks of <4% as potential cases
[14]. Peaks of 1-2% were considered to have HbA2’ trait
[14] while a diagnosis of homozygous A2’ was made
when HbA2’ was >2% with absent HbA2 [13]. We also
included samples with peaks less than 1% in the analy-
sis.(Table 1) Co-inheritance of HbA2’ and b-thalassae-
mia (double heterozygote) was suggested where sum of
HbA2 and HbA2’ was greater than 3.5% of total hemo-
globin [13].
Using a computerized data system of laboratory,
HPLC chromatograms preceding the identified cases
were checked for diagnosis of HbS to exclude a carry-
over effect.
Data entry and analysis was done using the Statistical
Package for Social Sciences (SPSS-14.0). Descriptive sta-
tistics were calculated which included maximum and
minimum values, and means ± one standard deviation
for all continuous data. Means were compared using
independent sample t test, among groups with different
proportions of S-window peaks. A P- value of <0.05 was
considered significant. All data was kept anonymous
and the study was approved by institutional ethical
review committee.
For characterization of the mutation at molecular
level, we prospectively collected blood samples of sus-
pected cases of HbA2’. We amplified a 730 bp fragment
of δ g l o b i ng e n eb yP C Ru s i n gaf o r w a r dp r i m e r
(5’ATCTCAGGGCAAGTTAAGGG-3’)a tn u c l e o t i d e
positions -150 to -131 from the cap site and a reverse
primer (5’AATGTGGGAGAAGAGCAGGT-3’)a tp o s i -
tions 68-87 from the second intron of δ globin gene
[3]. The mutation was verified by direct nucleotide
sequencing of the amplified fragment as well as its
digestion with CfoI restriction enzyme. CfoIr e c o g n i z e s
and cleaves a site created by the mutation of GGC ®
CGC at codon 16 to generate two fragments of 480 and
250 bp.
Results
We reviewed 10186 chromatograms in the year 2006
identifying various hemoglobin variants as follows: b
-thalassaemia trait, b -thalassaemia major, Hb S disor-
ders, Hb Q and Hb D in 319(3%), 159(1.5%), 14(0.13%),
8(0.07%) and 7(0.06%) samples respectively. Another
192 cases (1.89%) with S-window peaks of <4% were
observed with retention time ranging from 4.32-4.62
minutes (mean 4.59 ± 0.05 minutes). While most of our
cases had retention times between 4.55-4.62 minutes as
reported in literature [14], we also observed six cases
Table 1 Analysis of 192 samples with suspected HbA2’ with varying S-window peaks
S-Window
Peaks
Total
Cases
n (%)
Retention Time
Range (min)
Mean ± SD
HbA2*
Range (%)
Mean ± SD
Cases with
HbA2 > 3.5%
n (%)
Cases with HbA2
+suspected HbA2’>3.5%
n (%)
Additionally suspected b-
thalassaemia minor n (%)
<1% 123 (64.2) 4.33-4.62
4.59 ± 0.04
1.0-7.0
3.22 ± 1.41
27 (22.6) 47 (39.5) 20 (16.9)
1-2% 63 (32.6) 4.32-4.62
4.59 ± 0.05
1.3-6.3
3.07 ± 1.08
10 (15.9) 51 (81) 41 (65.0)
>2% 6 (3.1) 4.44-4.61
4.56 ± 0.06
2.3-5.2
3.67 ± 1.05
3 (50) 6 (100) 3 (50)
All cases 192(100) 4.32-4.62
4.58 ± 0.05
1.0-7.0
3.19 ± 1.30
40 104 64
* Difference in HbA2 levels in three groups was statistically not significant.
The table shows retention time of small S-window peaks along with their HbA2 percentages and the frequency of additional cases suspected of b-thalassaemia
minor among 192 total cases.
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with retention times of 4.52-4.54 minutes. Table 1
reviews frequency of potential HbA2’ cases with respect
to various proportions (<1, 1-2 and >2%) of hemoglobin
variant. The table shows that 123 cases (64.2%) had S
window peaks of less than 1%. Retention time and levels
of HbA2 were not statistically different in these three
groups of samples with potential HbA2’ mutation.
Hemogram evaluation
Complete blood counts were available for 163 cases only
(Table 2). However owing to missing data the correct
diagnosis for anemia can be made for 149 patients only.
There were 20 subjects (6 males and 14 females) who
were not anemic with mean hemoglobin respectively as
14.1 ± 1.2 and 12.3 ± 0.9 g/dl (data not shown), while
1 2 9s u b j e c t s( 7 2m a l e sa n d5 7f e m a l e s )s h o w e dh y p o -
chromic microcytic anemia with mean hemoglobin of
7.7 ± 2.9 and 7.8 ± 2.2 g/dl in that order.
HPLC Chromatogram Analysis
For all cases, mean HbA2 level was 3.19 ± 1.30% (range
1.0-7.0%) and mean S-window level was 0.92 ± 0.48%
(range 0.3-3.5%). The observed range for total HbA2
(HbA2+S-window) was 1.60-8.70%.
During the study period, 319 samples were identified to
have b-thalassaemia trait with HbA2 >3.5%. When the
results were computed taking account of S-window peaks
as presumed HbA2’, an additional 64 new cases were
suggested of having b -thalassaemia trait. This was before
the genetic analysis was performed. Figure 1 shows chro-
matogram from a patient with S window peak.
Genetic Analysis
To confirm that these S-window peaks represent HbA2’,
we performed the RFLP based PCR on 13 blood sam-
ples, with S-window peaks ranging from 0.6 to 2.4%.
A fragment of 730 bp was amplified in each case but
the overnight incubation with the enzyme CfoI failed to
digest the PCR products in any sample (Figure 2). Direct
Table 2 Haematological parameters in 163 cases with
varying small s- window peaks
S-
Window
Peaks (N)
Hb
(g/dl)
Hct
(%)
RBC
(10
12/l)
MCV
(fl)
MCH
(pg)
<1% (105) 9.5 ± 2.5 30.5 ± 7.4 4.6 ± 1.0 66.6 ± 10.8 21.0 ± 4.6
1-2% (53) 6.5 ± 2.4 21.6 ± 6.9 3.5 ± 1.2 63.2 ± 12.0 19.2 ± 5.0
>2%(5) 4.8 ± 3.1 15.1 ± 9.3 2.0 ± 1.1 75.3 ± 14.8 24.1 ± 6.3
All cases
(163)
8.4 ± 2.9 27.1 ± 8.6 4.2 ± 1.3 65.8 ± 11.5 20.5 ± 4.9
The table shows haemoglobin, haematocrit, red cell counts and red cell
indices in 163 cases out of 192 total cases where these parameters were
available.
Figure 1 Chromatogram with suspected HbA2’. Chromatogram
in a patient with S-window peak of 2.4% (red arrow) and Hb A2 of
3.0% (Please note that this chromatogram was not included in this
study as it was identified outside the study duration, i.e. after 2006).
Figure 2 RFLP-PCR. Gel electrophoresis of PCR products after CfoI
digestion. Lane1: size marker (100 bp). Lane 2: wild type showing
730 bp fragments. Lanes 3-5: 730 bp of uncleaved amplified
fragments from samples with S window peak. Note that CfoI cleaves
the GCG/C site created by HbA2’ in delta gene of hemoglobin.
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mutation in these thirteen samples (Figure 3). The
entire 730 bp amplified fragment, containing the first
two exons of delta globin gene, was reviewed for any
other delta gene mutations, but was found to resemble
the wild type gene in all the cases.
Discussion of findings
This study gives an insight into the reliability of HPLC
for detecting HbA2’ cases in Pakistani population.
HPLC has been shown to be a reliable instrument for
the detection of HbA2’ in many parts of the world
[6,13,14]. We found that the trends (retention time etc.)
observed on HPLC chromatogram analysis in this study
were similar to that reported for HbA2’ in previously
published studies. However, we establish no evidence of
the existence of HbA2’ mutation in Pakistani population.
Here we compare the findings of our HPLC chroma-
togram analysis with previously published studies.
A mean retention time of 4.59 ± 0.05 minutes for
HbA2’ cases was observed in the study which was com-
parable to other reports [13,14]. An HPLC chromato-
gram displaying HbA2’ with retention time of 4.41
minutes was reported by Van Kirk et al [14]. We also
observed a few cases with lower than average retention
times. Retention time of a hemoglobin variant can
change with different lots of reagents (including the ion-
exchange column)[15]. The levels of HbA2 were found
to be higher than those of HbA2’ in all cases similar to
other published reports [2,6,14,16]. All cases with sus-
pected HbA2’ of >2% fell under the category of b-thalas-
saemia minor if S-window peak was taken into account,
which was also consistent with previously published
studies [10,14]. Despite the similarities of our HPLC
chromatogram analysis with HbA2’studies published
earlier, the mutation was absent on genetic analysis.
Sixty four percent cases in our study showed S-win-
dow peaks of less than 1%. Such low peaks (up to 0.6%)
have been reported earlier but were never confirmed at
molecular level [6,14]. Retention time of these cases was
also very similar to that reported for HbA2’ diagnosis by
chromatography. However, HbA2’ mutation was not
observed on molecular analysis in any of our analyzed
patients.
In the absence of HbA2’, what may have caused these
peaks? Many studies have reported double heterozygotes
with HbA2’ levels of >2% [2,6] and as high as 3.3% [10].
Blood transfusions in sickle cell disease may dilute HbS
to as low as 2.6% [14]. Therefore it is advisable to care-
f u l l ye v a l u a t eS - w i n d o wp eaks of 2-4% in relation to
clinical details and genetic analysis to exclude sickle cell
disease. But authors believe that as HbS elutes at 4.51
min [13] and all our cases except six had retention time
greater than 4.52 min, HbS was not expected in our
samples. Moreover, a peak of this size in S-window can
also be due to carry over, which was however excluded
in our study by careful inspection of previous samples’
results for having hemoglobin S. Hb Manitoba and
Montgomery have HPLC retention time (4.58 min)
identical to that of HbA2’, but they are easily identified
by their higher percentages (15.7 to 16.5%) [13]. Eng
et al reported cases with a variant of HbA2 with same
mobility on starch gel electrophoresis as HbA2’ [17].
This was designated as HbA2-Indonesia and was later
found to be a2δ2
16 Gly ® Arg [18]. In our study, nucleo-
tide sequencing of the amplified DNA segment excluded
all mutations in the first two exons of delta globin gene.
There is a possibility that some of these small peaks
m a yb ed u et oa chain variants having a thalassaemia
phenotype, or a novel mutation. As many as 30 hemo-
globin variants elute in S-window on HPLC with over-
lapping retention times[15]. Unfortunately, because of
limited funds, we could not go into this depth of
analysis.
Methemoglobin produces a peak similar to that of a
delta chain variant on HPLC and hinders chromatogram
interpretation [19]. Hemoglobin in blood samples may
spontaneously oxidize to methemoglobin secondary to
inherited or acquired cause. Inherited causes are asso-
ciated with high hematocrit which was not seen in any
of our patients, and acquired methemoglobinemia is a
life threatening condition. Thus, indirect evidences
exclude this possibility. Laboratory error may also be
responsible for such peaks in our study, and an attempt
will be made at recalibrating the instrument, before pro-
ceeding with further genetic studies. Authors believe
that samples with small S-window peaks should be
Figure 3 Gene Sequencing. DNA sequence derived from a healthy
control (upper) and from a patient with S window peak (lower). The
sequencing chromatogram shows the same sequence in both
individuals [GCCCTGTGGGGCAAAGTGAA] with the arrows indicating
the peaks where HbA2’ mutation was expected.
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ance of these peaks. In either case, it is of critical impor-
t a n c et oe n s u r et h ep r e s e n c eo fH b A 2 ’ at molecular
level.
In Pakistan, the diagnosis of b-thalassaemia, whether
major or minor bears a social stigma. Hence, we must
exercise an utmost care when diagnosing this condition
and should do so at the highest level of certainty. In the
years to come, many other laboratories in Pakistan will
acquire HPLC. Only a few places have the resources to
perform genetic analysis. In our study, 64 additional
cases would have been labelled as b-thalassaemia minors
as per identification of HbA2’ by HPLC, if genetic analy-
sis was not performed. Hence, we report our negative
results to avoid future diagnostic dilemmas in underpri-
vileged laboratories and prevent incorrect labeling of
patients as b-thalassaemia minors.
Strengths and Limitations
This is the first report that addresses the suspected
HbA2’ cases from Pakistan. An attempt was made to
determine the true nature of these peaks by PCR ampli-
fication and nucleotide sequencing. As AKUH labora-
tory receives blood samples from all over the country
our results are expected to represent the entire
population.
One of the weaknesses of the study was failure to
identify the true nature of these small S-window peaks
including evaluation of exon3 of delta globin gene. The
peaks could be equally due to a novel delta chain variant
or a-thalassaemia with a similar retention time.
Conclusions
HbA2’ was not detected in potential cases identified by
HPLC in the Pakistani population. Hence, small S-
window peaks obtained on HPLC should not be
reported as HbA2’ unless confirmed at the genetic level.
Routine genetic studies are not cost effective and thus,
not recommended. We recommend further larger mole-
cular studies to determine the true nature of these
peaks.
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